Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.49 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | IDH1 | O75874 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.44 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.44 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29478750 | 1.00 | GLA (0.50) | GLAMEP1AMEP1BENPP2CYP19A1 | |
| Bromide SCHEMBL29784624 | 0.98 | GLA (0.49) | GLAMEP1AMEP1BENPP2CYP19A1 | |
| Ammonia Solution, Strong SCHEMBL3939346 | 0.91 | LMNA (0.44) | GLAMEP1AMEP1BENPP2CYP19A1 | |
| SCHEMBL688074 | 0.88 | PRKCI (0.53) | ENPP2CYP11B1CYP11B2 | |
| SCHEMBL4030533 | 0.85 | GSK3B (0.54) | MEP1AMEP1BFFAR1LMNAGSK3B | |
| SCHEMBL15494643 | 0.84 | CYP11B1 (0.48) | CYP11B1CYP11B2FFAR1FFAR4 | |
| SCHEMBL3166642 | 0.84 | MAOA (0.42) | GLAMEP1AMEP1BENPP2CYP19A1 | |
| SCHEMBL320197 | 0.83 | HRH3 (0.49) | GLAMEP1AMEP1BENPP2CYP19A1 | |
| SCHEMBL31088387 | 0.83 | GLA (0.47) | GLAMEP1AMEP1BENPP2CYP19A1 | |
| SCHEMBL2154019 | 0.82 | GLA (0.53) | GLAMEP1AMEP1BENPP2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 903 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4141002-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-03-01 | — | — | EP | claimed |
| US-11572366-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-02-07 | — | — | US | claimed |
| WO-2022151968-A1 | METHOD FOR PURIFYING KEY INTERMEDIATES OF CITALOPRAM | 浙江华海药业股份有限公司 | 2022-07-21 | — | — | WO | claimed |
| CN-113557236-B | Bifunctional immunomodulator, pharmaceutically acceptable salt thereof and pharmaceutical composition | 中国科学院广州生物医药与健康研究院 | 2022-05-10 | — | — | CN | claimed |
| CN-113557236-A | Bifunctional immunomodulator, pharmaceutically acceptable salt thereof and pharmaceutical composition | 中国科学院广州生物医药与健康研究院 | 2021-10-26 | — | — | CN | claimed |
| US-20210221819-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-07-22 | — | — | US | claimed |
| WO-2020248908-A1 | BIFUNCTIONAL IMMUNOMODULATOR, AND PHARMACEUTICALLY ACCEPTABLE SALT AND PHARMACEUTICAL COMPOSITION THEREOF | 中国科学院广州生物医药与健康研究院 | 2020-12-17 | — | — | WO | claimed |
| EP-3377488-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2018-09-26 | — | — | EP | claimed |
| US-20170145025-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-05-25 | — | — | US | claimed |
| EP-2970328-B1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-04-26 | — | — | EP | claimed |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | claimed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| US-6187945-B1 | TRANSFORMING AN AMINOMETHYL GROUP OF A CYANOBENZYLAMINE COMPOUND INTO A HYDROXYMETHYL GROUP, A HALOMETHYL GROUP, OR AN ACYLOXYMETHYL GROUP BY DIAZOTIZATION AND HYDROXYLATION, HALOGENATION OR ACYLATION | SHOWA DENKO K.K. (JP) | 2001-02-13 | — | — | US | claimed |
| EP-1004574-A1 | Process for producing cyanobenzyl compounds | Showa Denko Kabushiki Kaisha (JP) | 2000-05-31 | — | — | EP | claimed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| EP-0365328-B1 | Pyridine derivatives | ZENECA LTD (GB) | 1996-04-03 | — | — | EP | claimed |
| US-5053415-A | Antiischemic, antiinflammatory, antiarthritic agents, cardiovascular disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-10-01 | — | — | US | claimed |
| EP-0365328-A2 | Pyridine derivatives | ZENECA LIMITED (GB) | 1990-04-25 | — | — | EP | claimed |
| US-4348393-A | ANTIDEPRESSANTS | DELALANDE S.A. (FR) | 1982-09-07 | — | — | US | claimed |
| US-4346102-A | ANTIDEPRESSANTS | DELALANDE S.A. (FR) | 1982-08-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221819-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | GLA 1384/4885MEP1A 1097/4885MEP1B 1008/4885 |
| US-20170145025-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | GLA 1384/4885MEP1A 1097/4885MEP1B 1008/4885 |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, PLTP | GLA 2556/4885MEP1A 1809/4885MEP1B 1016/4885 |
| US-11572366-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | GLA 1384/4885MEP1A 1097/4885MEP1B 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.